Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6962361 | 0.88 | EGFR (0.43) | EGFRERBB2LMNAMAOBMAOA | |
| SCHEMBL6961120 | 0.84 | LMNA (0.47) | EGFRERBB2LMNAMAOBL3MBTL1 | |
| SCHEMBL6962368 | 0.83 | MRGPRX4 (0.51) | EGFRERBB2LMNAMAOBL3MBTL1 | |
| SCHEMBL22967587 | 0.82 | EGFR (0.51) | EGFRERBB2LMNAMAOBL3MBTL1 | |
| SCHEMBL6961577 | 0.82 | EGFR (0.61) | EGFRERBB2 | |
| SCHEMBL17489331 | 0.82 | EGFR (0.47) | EGFRERBB2LMNAMAOBMAOA | |
| SCHEMBL11949601 | 0.80 | EGFR (0.49) | EGFRERBB2MAOBMAOAKDM4E | |
| SCHEMBL4028363 | 0.78 | MAOB (0.57) | EGFRERBB2LMNAMAOBMAOA | |
| SCHEMBL22874578 | 0.77 | MAOB (0.60) | LMNAMAOBMAOAKDM4EALDH1A1 | |
| SCHEMBL15701549 | 0.77 | EGFR (0.47) | EGFRERBB2LMNAMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | EGFR 2/4885ERBB2 1/4885LMNA 4634/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | EGFR 2/4885ERBB2 1/4885LMNA 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.